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Optimal Antithrombin Activity Threshold for
Initiating Antithrombin Supplementation in
Patients With Sepsis-Induced Disseminated
Intravascular Coagulation: A Multicenter
Retrospective Observational Study
Mineji Hayakawa, MD, PhD 1, Kazuma Yamakawa, MD, PhD2,
Daisuke Kudo, MD, PhD3, and Kota Ono, MPH4
Abstract
Low-dose antithrombin supplementation therapy (1500 IU/d for 3 days) improves outcomes in patients with sepsis-induced
disseminated intravascular coagulation (DIC). This retrospective study evaluated the optimal antithrombin activity threshold to
initiate supplementation, and the effects of supplementation therapy in 1033 patients with sepsis-induced DIC whose antith-
rombin activity levels were measured upon admission to 42 intensive care units across Japan. Of the 509 patients who had
received antithrombin supplementation therapy, in-hospital mortality was significantly reduced only in patients with very low
antithrombin activity (43%; bottom quartile; adjusted hazard ratio: 0.603; 95% confidence interval: 0.368-0.988; P ¼ .045).
Similar associations were not observed in patients with low, moderate, or normal antithrombin activity levels. Supplementation
therapy did not correlate with the incidence of bleeding requiring transfusion. The adjusted hazard ratios for in-hospital mortality
increased gradually with antithrombin activity only when initial activity levels were very low to normal but plateaued thereafter.
We conclude that antithrombin supplementation therapy in patients with sepsis-induced DIC and very low antithrombin activity
may improve survival without increasing the risk of bleeding.
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Introduction
The activation of systemic coagulation and consequent disse-
minated intravascular coagulation (DIC) is frequently observed
in patients with sepsis and septic shock.1-3 Reduced plasma
levels of physiological anticoagulants, including antithrombin
(AT) and protein C, serve as markers of systemic coagulation
activation.2,3 Particularly, decreased AT activity is a conse-
quence of excessive thrombin generation,4 increased vascular
permeability,5 accelerated AT degradation,6 and impaired AT
synthesis during sepsis-induced DIC7 and is significantly asso-
ciated with high mortality rates.8,9
Several randomized controlled trials have investigated the
effects of high-dose AT administration in patients with sep-
sis.10-14 Although some have reported beneficial effects,10-12
the large KyberSept trial failed to show any overall beneficial
effect of high-dose AT administration in the study population.13
However, a subgroup analysis of the KyberSept trial demon-
strated that AT administration significantly improved survival
in patients with sepsis-induced DIC.15 Furthermore, a recent
meta-analysis of 3 randomized control trials by Umemura
et al16 indicated in that although AT administration yielded
survival benefits in patients with sepsis-induced DIC, such
positive effect was not seen in all patients with sepsis. They also
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concluded that anticoagulant therapy increased the overall inci-
dence of bleeding complications in patients with sepsis, but not
in patients with sepsis-induced DIC.16
Several recent studies revealed that low-dose AT supple-
mentation therapy (1500 IU/d for 3 days) improved treatment
outcomes in patients with sepsis-induced DIC and decreased
AT activity.17-20 In Japan, although AT supplementation ther-
apy has been approved for patients with sepsis-induced DIC at
AT activity 70%, there is no clear threshold for optimal AT
activity to start supplementation. Therefore, we investigated
AT activity levels and the effects of AT supplementation in
patients with sepsis-induced DIC to determine the optimal AT
activity threshold at which supplementation therapy should
be initiated.
Materials and Methods
Patient Selection and Data Collection
The Japan Septic Disseminated Intravascular Coagulation
(J-SEPTIC DIC) study (University Medical Information
Network Clinical Trials Registry number UMIN000012543),
a retrospective observational study, was conducted in
42 intensive care units (ICUs) at 40 institutions across Japan.
The study was approved by the institutional review board of
each participating hospital, and the need for informed consent
was waived because of its retrospective design.
Patients admitted to the participating ICUs for the treatment
of severe sepsis or septic shock between January 2011 and
December 2013 were included in the J-SEPTIC DIC study. The
definitions of “severe sepsis” and “septic shock” were based on
the definitions issued by the International Sepsis Definitions
Conference.21 Patients were excluded if they were younger
than 16 years or developed severe sepsis/septic shock after
admission to the ICU.
The J-SEPTIC DIC study retrospectively collected the fol-
lowing data: ICU characteristics; ICU admission route; patient
age, sex, and body weight; preexisting organ dysfunction and
hemostatic disorders; Acute Physiology and Chronic Health
Evaluation (APACHE) II score; Sequential Organ Failure
Assessment (SOFA) score; systemic inflammatory response
syndrome (SIRS) score; primary infection site; blood culture
results; microorganism(s) causing sepsis; daily results of
laboratory tests; adjunctive treatments; number of transfusions
needed; bleeding complications; and hospital outcomes.
Details of the collected data have been described in previous
reports.19,22 The DIC scores were calculated using a scoring
algorithm developed by the Japanese Association for Acute
Medicine,23 and missing values were scored as zeroes. Partici-
pants without preexisting hemostatic disorders who had single-
day DIC scores 4 during the first week after ICU admission
were considered patients with DIC. We previously reported the
results of several analyses based on data from the J-SEPTIC
DIC study.19,22,24,25
In the present investigation, patients with sepsis-induced
DIC and measured AT activity at the time of ICU admission
were selected from the patients included in the J-SEPTIC DIC
study. Patients with DIC received AT supplementation ther-
apy at the discretion of the attending physician and were
accordingly stratified into 2 groups: the AT group included
patients who received AT supplementation therapy, and the
control group included patients who did not receive AT
Patients with severe sepsis/septic shock 
n = 3195
Control group
n = 524
AT group
n = 509
Excluded patients: n = 1411
• Patients without DIC: n = 1000
• Pre-existing hemostaticdisorder: n = 411
DIC patients
n = 1784
DIC patientswith AT measurementon ICU admission
n = 1033
Excluded patients: n = 751
• No AT activity measurement on ICU admission: n = 751
Figure 1. Study design for the selection of patients with DIC. AT indicates antithrombin; DIC, disseminated intravascular coagulation;
ICU, intensive care unit.
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supplementation therapy. Although no AT supplementation
protocol was predefined, patients with DIC were typically
administered 1500 IU of AT per day. Antithrombin supple-
mentation therapy was continued for 3 days or until the
patient’s condition improved.
Statistical Analyses
Data are expressed as numbers (%), means (standard devia-
tions), or medians (interquartile ranges) as appropriate. Inter-
group comparisons were performed using the Mann-Whitney
U test and w2 test, and Spearman rank correlation coefficients
were calculated to determine the correlations between 2
variables.
An adjusted mortality analysis using propensity scores
was performed to address the existing differences in the
baseline characteristics between the AT and control groups
Table 1. Characteristics of Patients With Sepsis-Induced DIC.a,b
Control
AT
Supplementation
P
Valuen ¼ 524 n ¼ 509
ICU characteristics
General ICU 219 (42) 242 (48) .069
Emergency ICU 305 (58) 267 (53)
ICU management policy
Closed policy 354 (68) 275 (54) <.001
Open policy 84 (16) 123 (24)
Other 86 (16) 111 (22)
Number of beds 12 (8-20) 10 (7-15) <.001
Age, years 68 (1) 70 (1) .345
Male sex 298 (57) 282 (55) .661
Body weight, kg 56.9 (0.6) 55.9 (0.6) .181
Admission route to ICU
Emergency department 225 (43) 202 (40) .031
Other hospital 181 (35) 156 (31)
Hospital ward 118 (23) 151 (30)
Preexisting organ dysfunction
Liver insufficiency 7 (1) 7 (1) 1.000
Chronic respiratory
disorder
21 (4) 14 (3) .304
Chronic heart failure 37 (7) 24 (5) .115
Chronic hemodialysis 37 (7) 30 (6) .452
Immunocompromised 67 (13) 58 (11) .506
Severity
APACHE II score 23 (17-29) 25 (18-30) .064
SOFA score
Total 10 (7-12) 11 (8-14) <.001
Respiratory 2 (1-3) 2 (1-3) .436
Renal 2 (0-3) 2 (1-3) .007
Liver 0 (0-1) 0 (0-1) .022
Cardiovascular 3 (0-4) 3 (2-4) <.001
Coagulation 1 (0-2) 2 (1-2) <.001
Central nervous 1 (0-3) 1 (0-3) .389
DIC score 5 (4-6) 6 (4-7) <.001
SIRS score 3 (3-4) 3 (2-4) .531
Primary infection site
Abdomen 160 (31) 192 (38) .069
Lung 126 (24) 91 (18)
Urinary tract 98 (19) 106 (21)
Bone/soft tissue 61 (12) 60 (12)
Cardiovascular 15 (3) 10 (2)
Central nervous system 19 (4) 10 (2)
Catheter related 6 (1) 7 (1)
Others 8 (2) 11 (2)
Unknown 31 (6) 22 (4)
Blood culture
Positive 252 (48) 283 (56) .039
Negative 254 (48) 215 (42)
Not taken 18 (3) 11 (2)
Microorganisms causing sepsis
Gram-negative rod 198 (38) 241 (47) .007
Gram-positive coccus 136 (26) 125 (25)
Fungus 6 (1) 4 (1)
Virus 6 (1) 2 (0)
Mixed infection 64 (12) 56 (11)
Other 17 (3) 4 (1)
Unknown 97 (19) 77 (15)
(continued)
Table 1. (continued)
Control
AT
Supplementation
P
Valuen ¼ 524 n ¼ 509
Laboratory results on admission to ICU
White blood cell count,
109/L
11.9 (5.7-19.3) 11.4 (3.8-18.8) .209
Platelet count, 109/L 112 (59-183) 82 (50-140) <.001
Hemoglobin, mmol/L 11.0 (9.1-12.8) 10.4 (8.9-12.2) .003
PT-INR 1.3 (1.2-1.5) 1.4 (1.3-1.7) <.001
Fibrinogen, g/L 424 (278-589) 350 (225-513) <.001
FDP, mg/L 26.6 (15.0-59.2) 25.8 (14.8-63.8) .879
D-dimer, mg/L 13.6 (6.2-29.2) 13.3 (6.1-27.9) .696
AT activity, % 60 (48-75) 51 (40-61) <.001
Lactate, mmol/L 2.9 (1.7-5.7) 3.9 (2.3-6.7) <.001
Coadministered anti-DIC drug
Recombinant
thrombomodulin
161 (31) 285 (56) <.001
Protease inhibitors 45 (9) 121 (24) <.001
Heparinoids 29 (6) 44 (9) .033
Other therapeutic intervention
Surgical intervention 192 (37) 252 (50) <.001
Immunoglobulin 139 (27) 286 (56) <.001
Low-dose steroid 136 (26) 184 (36) <.001
RRT 147 (28) 223 (44) <.001
Nonrenal indication
RRT
38 (7) 72 (14) <.001
PMX-DHP 87 (17) 200 (39) <.001
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; AT,
antithrombin; DIC, disseminated intravascular coagulation; FDP, fibrin/fibrino-
gen degradation products; ICU, intensive care unit; PMX-DHP, polymyxin B-
direct hemoperfusion; PT-INR, prothrombin time-international normalized
ratio; RRT, renal replacement therapy; SIRS, systemic inflammatory response
syndrome; SOFA, Sequential Organ Failure Assessment.
aClosed policy, in ICU with closed policy, intensivists are the patient’s primary
attending physician or are consulted as part of mandatory critical care; open
policy, in ICU with open policy, intensivists are unavailable or are involved in
the care only when the attending physician requests a consultation.
bData are expressed as numbers (%), means (SD), or medians (interquartile
ranges). Patients were stratified into 2 groups according to whether or not
they received AT supplementation therapy.
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caused by the retrospective nature of the study.26,27 The
findings of various therapeutic interventions were used to
estimate the propensity score because such investigations
were usually performed simultaneously with AT supplemen-
tation, and the resulting scores were stratified into quintiles.
To estimate the propensity scores, data were fitted to a
logistic regression model in which AT treatment was set
as a function of several variables, including patient charac-
teristics, therapeutic interventions, and ICU characteristics.
This resulted in models based on age, sex, body weight,
admission route to the ICU, preexisting organ dysfunction,
APACHE II score, total SOFA score on day 1, SIRS score
on day 1, DIC score on day 1, primary infection site, blood
culture results, microorganisms responsible for sepsis,
laboratory tests (including white blood cell count, platelet
count, hemoglobin level, AT activity level, and prothrombin
time-international normalized ratio) on day 1, use of anti-
DIC drugs, immunoglobulin use, low-dose steroid use, sur-
gical interventions at the infection site, renal replacement
therapy, renal replacement therapy for nonrenal indications,
polymyxin B-direct hemoperfusion, ICU characteristics,
ICU management policy, and the number of beds in the
ICU. Some laboratory results (fibrinogen, fibrin/fibrinogen
degradation product, D-dimer, and lactate levels) were not
used to estimate propensity scores because the proportions
of missing data in these categories exceeded 5%.
Patients were stratified into 4 subsets corresponding to the
quartiles of AT activities distribution, recorded upon ICU
admission. The overall association between AT supplementa-
tion therapy and mortality outcomes was assessed using a Cox
regression model with the propensity score strata as a covariate.
For bleeding complications, the odds ratio and associated 95%
confidence intervals (CIs) were estimated using a logistic
regression model with the propensity score strata as the covari-
ate. SPSS version 22.0 J (SPSS Inc, Chicago, Illinois) was used
for all statistical analyses. The level of statistical significance
was set at P < .05.
Results
A total of 3195 patients with severe sepsis/septic shock were
enrolled in the J-SEPTICDIC study. Among these, 1784 patients
were diagnosed with DIC, but AT activity levels measured upon
ICU admission (day 1) were available only for 1033 patients; of
these, 509 received AT therapy, while 524 did not (Figure 1).
The characteristics of the patients with DIC with available day 1
AT activity measurements are presented in Table 1.
The relationships between APACHE II scores, SOFA
scores, and AT activity levels upon ICU admission are pre-
sented in Figure 2. A strong correlation was observed between
the APACHE II score and SOFA score (r ¼ 0.568; P < .001).
However, the AT activity on ICU admission did not correlate
strongly with neither the APACHE II score (r ¼ 0.097; P ¼
.002) nor SOFA score (r ¼ 0.223; P < .001).
The C-statistic for the calculated propensity score was 0.815
and the Hosmer-Lemeshow w2 value was 7.010 (df ¼ 8), with a
nonsignificant P value of .536 for the goodness of fit. The strati-
fication of sepsis-induced DIC patients, based on AT activity
upon ICU admission, yielded the following quartile-based sub-
sets: very low AT activity (43%), low AT activity (44%-55%),
moderate AT activity (56%-69%), and normal AT activity
(70%). This approach led to similar sample sizes among the
quartile-based patient subsets (ie, each group corresponded to one
quartile of the distribution of AT activities recorded upon ICU
admission). The characteristics of patients with sepsis-induced
DIC stratified by AT activity level are presented in Table 2.
A Cox regression analysis revealed AT supplementation ther-
apy significantly reduces mortality (adjusted hazard ratio: 0.603;
95% CI: 0.368-0.988; P ¼ .045) in patients with sepsis-induced
DIC and very low AT activity (43%; bottom quartile). How-
ever, no association between AT supplementation and survival
was observed in patients with low, moderate, or normal AT
activity. The subset-specific adjusted hazard ratios (95% CI) and
P values were as follows: low AT activity: 0.921 (0.559-1.515),
P ¼ .745; moderate AT activity: 1.309 (0.713-2.404), P ¼ .385;
Figure 2. Scatter plots of APACHE II scores, SOFA scores, and AT activities. A strong correlation was observed between the APACHE II and
SOFA scores (r ¼ 0.568; P < .001). However, no strong correlation was observed between AT activity on ICU admission and the APACHE II
score (r ¼ 0.097; P ¼ .002) or SOFA score (r ¼ 0.223; P < .001). APACHE indicates Acute Physiology and Chronic Health Evaluation; AT,
antithrombin; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.
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and normal AT activity: 0.607 (0.316-1.172), P¼ .138. Survival
curves for patients with very low AT activity in the AT supple-
mentation group and the control group are presented in Figure 3.
Table 3 summarizes the incidence of bleeding complica-
tions in each quartile subset in relation to AT supplementation
therapy (AT supplementation vs control). There was no sig-
nificant correlation between AT supplementation therapy sta-
tus and the incidence of bleeding complications requiring
transfusion, regardless of the AT activity level upon ICU
admission. No bleeding-related death events occurred during
the observation period. Additionally, the adjusted hazard
ratios for inpatient mortality were found to increase gradually
with each 10% increment in the AT activity threshold from
very low to normal but remained relatively constant thereafter
(Figure 4).
Discussion
This multicenter, nationwide, retrospective, observational
study revealed that patients with sepsis-induced DIC and very
low AT activity (43%) were optimal candidates for AT sup-
plementation therapy. Furthermore, AT supplementation ther-
apy was not found to increase bleeding complications in this
patient subset. Some previous clinical trials included sepsis
patients with AT activity levels 70%, which was approved
for the initiation of AT supplementation therapy by the Minis-
try of Health, Labor, and Welfare in Japan.11,28-30 Hence,
although the reports of these trials did not explicitly discuss
the basis of the selected AT activity threshold values,11,28-30
these thresholds were most likely based on the normal range of
AT activity (70%-120%).31 Although the KyberSept trial
included patients with severe sepsis, irrespective of AT activ-
ity, more than 45% of the patients had AT activity levels
<60%.13 A post hoc analysis of said study revealed patients
with sepsis-induced DIC were more likely to have AT activity
levels <60% than those without sepsis-induced DIC (72% vs
15%). Furthermore, AT administration significantly improved
survival in patients with sepsis-induced DIC.15 Therefore, AT
administration therapy may be more effective in patients with
lower AT activity.
Through nonrandomized multicenter postmarketing sur-
veys, Iba et al32,33 also reported that AT supplementation ther-
apy was more effective in patients with DIC and decreased AT
activity. Specifically, patients with DIC and an AT activity
<40%, who were treated with 3000 IU AT per day had higher
rates of survival and recovery from DIC than did those treated
1500 IU AT per day, without any increased risk of bleeding
complications,33 a level of activity close to what we observed
in the present study.
Antithrombin, an important physiologic anticoagulant, inhi-
bits an estimated 80% of the coagulation activities of thrombin
and coagulation factors X, IX, VII, XI, and XII.34 However, AT
activity is frequently decreased in sepsis-induced DIC4-7 and is
associated with high disease severity and mortality.8,9 A recent
study revealed AT interacts with vascular endothelial cells35
and protects them by binding to glycosaminoglycans and sup-
pressing capillary leakage,36 which in itself is found to exert
anti-inflammatory effects during sepsis.37 Therefore, AT sup-
plementation may improve outcomes in patients with sepsis
and decreased AT activity.
In the present study, we stratified patients into 4 subsets
corresponding to the quartiles of AT activity distribution.
Although some studies used the classification and regression
trees method to categorize patients,24,38 we used quartile-based
stratification because the quartile is the most popular nonpara-
metric criterion and can be used to group patients into compar-
ably sized subsets.
The present study had several limitations due to its retro-
spective design. Hence, the results should be considered with
Figure 3. Survival curves in patients with sepsis-induced DIC and AT
activity 43%. Antithrombin supplementation therapy significantly
reduces mortality in patients with sepsis-induced DIC and very low
AT activity. The solid line represents survival in the group receiving
AT supplementation therapy (AT group), whereas the dotted line
represents survival in the control group (ie, no AT supplementation
therapy). AT indicates antithrombin; DIC, disseminated intravascular
coagulation; ICU, intensive care unit.
Table 3. Relationship Between AT Levels and Incidence of Bleeding
Complications.a
AT Activity on
ICU Admission Adjusted Odds Ratio (95% CI) P Value
Very low 43% 0.942 (0.421-2.108) .89
Low 44-55% 0.555 (0.241-1.277) .17
Moderate 56-69% 0.579 (0.231-1.456) .25
Normal 70% 0.608 (0.228-1.620) .32
Abbreviations: AT, antithrombin; CI, confidence interval; ICU, intensive care
unit.
aBleeding event data are expressed as number (%). Patients were first stratified
into 4 groups corresponding to the distribution quartiles of AT activity levels
upon ICU admission and were further stratified according to whether or not
they received AT supplementation therapy. P values are given for the compar-
ison between the AT supplementation group and control group in each AT
activity quartile.
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care. The most significant limitation is that we could not iden-
tify the exact timing and duration of therapeutic interventions.
However, AT supplementation therapy was usually adminis-
tered simultaneously with other therapeutic interventions upon
ICU admission, which were unaffected by AT supplementation
therapy. Therefore, we considered it acceptable to use these
therapeutic interventions for estimating the propensity scores.
Second, the AT activities of patients with sepsis-induced DIC
were not measured in more than 40% of cases upon ICU admis-
sion, as measurement of AT activity is not common practice in
emergency settings in Japan. These patients were excluded
from the present analysis. Third, detailed information on the
cause of death was unavailable in the present study. Fourth, the
baseline clinical risk factors for a bleeding tendency were not
evaluated, although their effects may be reflected in the esti-
mation of propensity scores. Fifth, the data set was occasionally
incomplete for specific laboratory results (fibrinogen, fibrin/
fibrinogen degradation products, D-dimers, and lactate levels)
upon ICU admission.
In conclusion, our findings suggest that the optimal candi-
dates for AT supplementation therapy for sepsis-induced DIC
were not those with 70% AT activity but those with very low
AT activity (<43%). In this specific patient subset, AT supple-
mentation therapy may improve survival rates without
increasing the risk of bleeding complications.
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